EXPRESS MAIL NO. EV 452 772 615 US

ATTY DOCKET NO.	APPLICATION NO
8449-156-999	09/369,941
APPLICANT	
Kensil C.	
FILING DATE	GROUP
August 6, 1999	1632

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D01	4,469,863	09/04/84	Ts'o et al.			
	D02	4,522,811	6/11/85	Eppstein et al.			
	D03	5,023,243	6/11/91	Tullis			
	D04	5,057,540	10/15/91	Kensil et al.			
	D05	5,273,965	12/28/93	Kensil et al.			
	D06	5,352,449	10/4/94	Beltz et al.			
	D07	5,443,829	8/22/95	Kensil et al.			
	D08	5,583,112	12/10/96	Kensil et al.			
	D09	5,650,398	7/22/97	Kensil et al.			
	D10	5,977,081	11/2/99	Marciani			
	D11	6,231,859	5/15/01	Kensil			
	D12	6,524,584	2/25/03	Kensil			
	D13	6,544,518	4/8/03	Friede et al.			
	D14	6,558,670	5/6/03	Friede et al.			
	D15	6,645,495	11/11/03	Kensil et al.			
	D16	2002/0164341	11/7/02	Davis et al.			
	D17	2003/0091599	5/15/03	Davis et al.			
	D18	2003/0224010	12/4/03	Davis et al.			
	D19	2003/0161834	4/28/03	Friede et al.			
	D20	09/760,506		Kensil et al.			01/12/01

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	E01	WO 02/32450	4/25/02	PCT				
	E02	WO 98/37919	9/3/98	PCT				
	E03	WO 95/26204	10/5/95	PCT				
	E04	WO 98/40100	9/17/98	PCT				
	E05	BE 9908885	4/19/99	Belgium				
	E06	EP 1005368	3/10/98	Europe				

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

F01	Agrawal et al., 1988, Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci U S A. 85(19):7079-7083.
F02	Agrawal S. 1992, Antisense oligonucleotides as antiviral agents. Trends Biotechnol. 10(5):152-158
F03	Beaucage et al., 1981, Deoxynucleotide phosphoramidites - A new class of key intermediates for deoxypolynucleotide synthesis. Tet. Let. 22:1859-1862

7-27-04

	F04	Boggs et al., 1997, Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev. 7(5):461-471
	F05	Campbell & Peerbaye, 1992, Saponin. *Res. Immuno.* 143:526-530
	F06	Carson et al., 1997, Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 186(10):1621-1622
	F07	Chavali & Campbell, 1987, Immunomodulatory Effects of Orally-Administered Saponins and Nonspecific Resistance Against Rabies Infection. *Int. Archs. Allergy Appl. Immun.* 84:129-134
	F08	Chavali et al., 1988, Immunopotentiation by Orally-Administered *Quillaja* Saponins : Effects in Mice Vaccinated Intraperitoneally Against Rabies. *Clin. Exp. Immunol.* 74:339-343
	F09	Chavali et al., 1987, An *In Vitro* Study of Immunomodulatory Effects of Some Saponins. *Int. J. Immunopharmac.* 9(6):675-683
	F10	Dalsgaard, K. 1978, A study of the isolation and characterization of the saponin *quil a. Acta Veterinia Scandinavica* 69:1-40
	F11	Elkins et al., 1999, Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol. 162(4):2291-2298
	F12	Froehler B, 1986, Deoxynucleoside H-Phosphonate diester intermediates in the synthesis of internucleotide phosphate analogues. Tet. Let. 27:5575
	F13	Froehler et al., 1986, Synthesis of DNA via deoxynucleoside H-phosphonate intermediates. Nucleic Acids Res. 14(13):5399-5407
	F14	Gaffney et al., 1988, Large-scale oligonucleotide synthesis by the H-Phosphonate method. Tet. Let. 29:2619-2622
	F15	Garegg et al., 1986, Nucleoside H-phosphonates III. Chemical synthesis of oligodeoxyribonucleotides by the hydrogenphosphonate approach. Tet. Let. 27:4051-4054
	F16	Garegg et al., 1986, Nucleoside H-phosphonates IV. Automated solid phase synthesis of oligoribonucleotides by the hydrogenphosphonate approach. Tet. Let. 27:4055-4058
	F17	Goodchild, J. 1990, Conjugates of oligonucleotides and modified oligonucleotides: a review of their systhesis and properties. Bioconjugate Chem. 1:165
	F18	Higuchi et al. Structure of desacylsaponins obtained from the bark of *quillaja saponaria*. Phytochemistry 26:229-235
	F19	Kensil et al., 1992, Structure/Function relationship in adjuvants from Quillaja saponaria Molina. Vaccine 92 (Cold Spring Harbor Laboratory Press) pp. 35-40.:
	F20	Kim et al., 2001, Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine. 19(4-5):530-537
	F21	Kirkby et al., Effects of anticholinesterase drugs tacrine and E2020, the 5-HT3 antagonist ondansetron, and the H3 antagonist thioperamide, in models of cognition and cholinergic function. Behav Pharmacol. 1996 Nov;7(6):513-525.
	F22	Klinman et al., 1996, CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 93(7):2879-2883
	F23	Krieg et al., 1996, Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 6(2):133-139
	F24	Krieg et al., 1998, CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 161(5):2428-2434
	F25	Lipkin, 1995, "Vegemania: Scientists Tout the Heath Benefits of Saponins", *Science News* 148:392-393
	F26	Maharaj et al., 1986, Immune Responses of Mice to Inactivated Rabies Vaccine Administered Orally: Potentiaion by *Quillaja* Saponin. *Can. J. Microbiol.* 32:414-420
	F27	Marciani et al., 1991, Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. Vaccine. 9(2):89-96
	F28	Newman et al., 1992, Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J Immunol. 148(8):2357-2362
	F29	Rao & Sung, 1995, Saponins as Anticarcinogens. *J. Nutr.* 125:717S-724S,
	F30	Uhlmann et al., Antisense oligonucleotides: A new therapeutic principle. Chem. Rev. 9:544-584

EXAMINER	**DATE CONSIDERED** 7-27-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.